Although CREBH is upregulated in liver and Fgf21 production is increased by obesity, the capacity of the CREBH–Fgf21 axis to mitigate weight gain and obesity-related metabolic disorders is limited under natural conditions. Here, CREB3L3 is linked to Other metabolic disease.